Back to Journals » OncoTargets and Therapy » Volume 10

The effect of circulating miR-223 on surveillance of different cancers: a meta-analysis

Authors Zhang YF, Lin JB, Huang WJ, Cao Y, Liu Y, Wang TQ, Zhong WY, Wang DL, Mao RR, Chen XL

Received 24 March 2017

Accepted for publication 12 May 2017

Published 28 June 2017 Volume 2017:10 Pages 3193—3201


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ru Chen

Peer reviewer comments 2

Editor who approved publication: Dr Samir Farghaly

Yunfeng Zhang,1,* Jinbo Lin,2,* Wenjie Huang,3,* Yong Cao,4 Yi Liu,4 Tieqiang Wang,4 Weiyi Zhong,4 Dongli Wang,4 Rongrong Mao,4 Xiaoliang Chen4

1Surgical Operating Room, Longgang District People’s Hospital of Shenzhen, 2Medical Oncology, Longgang District Central Hospital of Shenzhen, 3Medical Oncology, Guangming District Central Hospital of Shenzhen, 4Chronic Disease Control and Prevention Center, Shenzhen Guangming District Center for Disease Control and Prevention, Shenzhen, China

*These authors contributed equally to this work

Purpose: Abnormal expression of miR-223 in cancerous tissue has confirmed it as an important player in tumorigenesis of cancers, such as hepatocellular carcinoma, colorectal carcinoma, osteosarcoma, gastric cancer, and chronic lymphocytic leukemia. The present meta-analysis aimed to explore the association between circulating miR-223 and prognosis of cancers.
Methods: The studies were accessed by an electronic search of multiple databases. RevMan5.3 and STATA14.0 were used to estimate the heterogeneity among studies, pooled effects, and publication bias.
Results: Ten studies with data of 1,002 patients with cancer were included in this meta-analysis. The risk of metastasis from stages 3 to 4 of TNM did not decrease when high versus low circulating expression of miR-223 were compared (pooled odds ratio =0.50, 95% CI: 0.24–1.03). In case of prognosis, the overall survival time was not significantly longer with high circulating miR-223 expression (pooled hazard ratio [HR] =0.64, 95% CI: 0.38–1.11) in all cancer types. However, the overall survival time of chronic lymphocytic leukemia (pooled HR =0.19, 95% CI: 0.07–0.54) increased in subgroup analysis. Moreover, the treatment-free survival of chronic lymphocytic leukemia was significantly increased with high circulating miR-223 expression (pooled HR =0.38, 95% CI: 0.23–0.64).
Conclusion: Circulating miR-223 was not an effective biomarker in prognosis surveillance in all cancers but in chronic lymphocytic leukemia.

Keywords: miR-223, carcinoma, metastasis, prognosis, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]